BioSpace News Archive

Velabs Therapeutics GmbH, a biotech company focused on the rapid screening of functional therapeutic antibodies announced that it has entered into an exclusive licence agreement with alytas therapeutics GmbH, for the development and commercialization of alytas’ antibodies in the field of senescence, related degenerative processes and pathologies.

FARE said the biomarker research project, which will be conducted at Janssen’s World Without Disease Accelerator, “has the potential to make a real and significant impact for the 32 million Americans living with food allergies.”

BioSpace spoke to leaders from various corners of the industry who provided their insights into what the coming year is likely to hold for their particular sphere.

If one of your goals is to go for that big promotion this year, there are a few things you can do now to get the ball rolling.

The funds will be used to support the development of its lead clinical assets under development as cancer treatments.

Pharma and biotech companies from across the globe provide business and pipeline updates.

Study showed that two metabolic enzymes in the proline metabolic pathway are potential targets to inhibit cancer cell growth, and offers new hope for effective liver cancer treatments

Polyganics announced that it has obtained CE marking for LIQOSEAL®, its easy-to-use and innovative dural sealant patch, and will launch the device in Europe with immediate effect.

Funding to Support Ongoing Advancement of siFi2, Lead Candidate from Company’s First-of-its-Kind Platform for Precisely Controlling Core Cell Migration Mechanisms

Signant’s TrialMax® eCOA platform and Propeller Health’s digital health platform connect to improve patient engagement and simplify data collection using real-time management and dose tracking